Breast Biopsy Devices Market Size, Share and Growth Outlook, 2026

Breast Biopsy Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Breast Biopsy Devices Market size is forecast to increase from $2.56 Billion in 2026 to $4.3 Billion in 2034 at a CAGR of 6.7% between 2026 and 2034.

The Breast Biopsy Devices market report provides detailed analysis and outlook of Breast Biopsy Devices segments including By Product Type (Biopsy Consumables, Biopsy Systems, Specimen Handling Systems), By Guidance Technology (Ultrasound-Guided, Stereotactic-Guided, MRI-Guided), By Application (Screening, Diagnostics, Therapy Response Monitoring), By End-User (Hospitals, Specialized Breast Care Centers, Diagnostic and Imaging Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Breast Biopsy Devices Industry Overview

Advanced Vacuum-Assisted Biopsy Systems Improving Diagnostic Efficiency

The breast biopsy devices industry is witnessing significant technological innovation aimed at improving tissue acquisition efficiency and diagnostic accuracy in challenging clinical scenarios. Multi-center comparative evaluations have highlighted the clinical utility of the Mammotome® Revolve EX dual vacuum-assisted breast biopsy platform. The system is specifically engineered to address anatomically complex breast lesions, including abnormalities located near the pectoralis major muscle where conventional biopsy procedures can be technically challenging. To support procedural flexibility, the platform offers five adjustable aspiration vacuum levels and three selectable tissue aperture window sizes of 12 mm, 18 mm, and 25 mm. Clinical findings demonstrated that configuring the device with the largest 25 mm aperture and maximum aspiration setting significantly reduced procedural time while retrieving approximately 4 grams of diagnostic tissue in as few as 10 continuous cuts. These capabilities enhance workflow efficiency and support more reliable pathological evaluation of suspicious breast lesions.

Radar-Based Localization Technologies Supporting Breast-Conserving Surgery

Technological advancements in lesion localization are transforming surgical planning and precision within breast oncology procedures. Long-term assessments documenting the evolution of breast localization technologies have highlighted the growing adoption of the SCOUT MD™ system. Unlike earlier single-reflector localization platforms that faced challenges related to signal overlap, SCOUT MD™ utilizes miniaturized 5 mm radar reflectors capable of generating up to four uniquely identifiable signal signatures. The FDA-cleared system enables surgeons to monitor the real-time depth and distance of multiple independent breast lesions or targeted lymph nodes through an interactive touchscreen console. This capability allows seamless localization of complex surgical targets during breast-conserving procedures, improving procedural accuracy while supporting personalized surgical planning. The growing use of advanced radar-guided localization technologies reflects increasing demand for precise, minimally invasive approaches to breast cancer treatment.

Contrast-Enhanced Mammography-Guided Biopsy Expanding Imaging Options

Breast imaging and biopsy technologies continue to evolve to address lesions that remain difficult to visualize using conventional imaging methods. Prospective clinical investigations have evaluated Contrast-Enhanced Mammography-Guided Biopsy (CEM-Bx) systems as an alternative to magnetic resonance imaging-guided biopsy procedures for lesions lacking tomosynthetic or sonographic visibility. In a study involving 184 complex breast lesions, contrast-enhanced mammography-guided systems demonstrated an overall precision sampling success rate of 57.6% when biopsy procedures were performed directly within the imaging suite. Multivariable regression analyses identified lower baseline background parenchymal enhancement (BPE) and larger lesion size as important factors associated with improved tissue sampling accuracy. The ability of CEM-Bx platforms to provide targeted sampling of otherwise difficult-to-access lesions is expanding diagnostic options for breast imaging specialists and strengthening the role of advanced contrast-enhanced technologies within modern breast cancer diagnosis pathways.

Breast Biopsy Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Breast Biopsy Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Hologic, Inc., Becton, Dickinson and Company (BD), Leica Biosystems , Argon Medical Devices, Inc., Cook Group Incorporated, Merit Medical Systems, Inc., Stryker Corporation, Planmed Oy, Sanarus Technologies. The Breast Biopsy Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Breast Biopsy Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Breast Biopsy Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Breast Biopsy Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Breast Biopsy Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Breast Biopsy Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Breast Biopsy Devices industry include- Hologic, Inc., Becton, Dickinson and Company (BD), Leica Biosystems , Argon Medical Devices, Inc., Cook Group Incorporated, Merit Medical Systems, Inc., Stryker Corporation, Planmed Oy, Sanarus Technologies. The Breast Biopsy Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Breast Biopsy Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Breast Biopsy Devices market remains one of the strongest-performing segments in the country.
The US Breast Biopsy Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Breast Biopsy Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Breast Biopsy Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Breast Biopsy Devices markets

Canada's strong Breast Biopsy Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Breast Biopsy Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Breast Biopsy Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Breast Biopsy Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Breast Biopsy Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Breast Biopsy Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Breast Biopsy Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Breast Biopsy Devices sales through 2034

France Breast Biopsy Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Breast Biopsy Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Breast Biopsy Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Breast Biopsy Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Breast Biopsy Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Breast Biopsy Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Breast Biopsy Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Breast Biopsy Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Breast Biopsy Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Breast Biopsy Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Breast Biopsy Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Breast Biopsy Devices Market Segmentation

By Product Type
Biopsy Consumables
Biopsy Systems
Specimen Handling Systems
By Guidance Technology
Ultrasound-Guided
Stereotactic-Guided
MRI-Guided
By Application
Screening
Diagnostics
Therapy Response Monitoring
By End-User
Hospitals
Specialized Breast Care Centers
Diagnostic and Imaging Centers
Ambulatory Surgical Centers

Top Companies in Breast Biopsy Devices Industry

Hologic, Inc.
Becton, Dickinson and Company (BD)
Leica Biosystems
Argon Medical Devices, Inc.
Cook Group Incorporated
Merit Medical Systems, Inc.
Stryker Corporation
Planmed Oy
Sanarus Technologies

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025